Abstract Background: Early care of benign paroxysmal positional vertigo (BPPV) is essential due to its detrimental effects on life quality. The objective of the current research was to evaluate the effectiveness of oral betahistine versus cinnarizine in BPPV treatment. Patients and Methods: An observational comparative study, in which 60 adult patients with BPPV were classified into two equal groups almost in similar age, gender, and degree of vertigo, based on their history and results from the Dix–HallPike test. Group “B” was given cinnarizine, while Group “A” was given betahistine, following a 21-day period. Every patient was reassessed, the provocation maneuver was carried out (success rate), and the mean vertigo score (MVS), Dizziness Handicap Inventory (DHI), and vertigo visual analog scale (VVAS) were reassessed for therapeutic efficacy. Results: Group “A”, the VVAS score was dropped from 69.65% pre-operatively to 21.45% post-operative, with statistically significant differences, as P = 0.021, in Group “B” was dropped from 70.83% to 61.72%, no statistically significant difference ( P = 0.873). The DHI score in Group “A” dropped from 47.75 pretreatment to 15.83 posttreatment; this was a statistically significant difference ( P = 0.01), while Group “B” had a nonstatistically significant drop ( P = 0.561) from 46.32 to 38.65. Group “A” experienced a statistically significant reduction in MVS from 2.35 to 0.179 following treatment ( P = 0.001), but Group “B” experienced a nonstatistically significant reduction from 2.83 to 2.15 ( P = 0.632). Overall success rate (80%); being 86.7% in Group “A”, and 73.4% in Group “B”. Conclusions: Betahistine oral intake shows better efficacy than cinnarizine in medical treatment of BPPV.
Mohammed Dawood (Tue,) studied this question.